{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:20:06Z","timestamp":1787743206149,"version":"build-2784847793"},"reference-count":36,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"unspecified","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Belgian and Luxembourgish Society for Pediatric Endocrinology and Diabetes","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["2103-05064"],"award-info":[{"award-number":["2103-05064"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonds de la Recherche Clinique","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100011068","name":"Fondation Saint-Luc","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100011068","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2026,8,1]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Impaired glucagon counterregulation is a major contributor to hypoglycemia risk in type 1 diabetes (T1D). While well described in adults, the timing, trajectory, and determinants of glucagon dysfunction in children remain poorly defined. Our objective was to characterize the evolution of glucagon secretion during insulin-induced hypoglycemia in children with newly diagnosed T1D and to identify biomarkers of counterregulatory failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>GLUcagon REsponse to hypoglycemia in children and adolescents with new-onset type 1 DIAbetes (GLUREDIA) - Work Package (WP) 1 is a prospective, multicenter longitudinal study including 22 children and adolescents (aged 2\u201317 years) with newly diagnosed T1D and eight healthy first-degree relatives. Participants underwent standardized insulin-induced hypoglycemia tests (IIHTs). In patients with T1D, IIHTs were performed at diagnosis and at 6, 12, and 18 months. Plasma glucagon and counterregulatory hormones were measured at baseline and during hypoglycemia. Continuous glucose monitoring (CGM) metrics and circulating biomarkers were analyzed using longitudinal mixed models and regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In healthy participants, IIHT elicited a robust physiological increase in glucagon during hypoglycemia (p&lt;0.001). In contrast, children with T1D showed no significant glucagon response despite deeper hypoglycemia. Longitudinally, glucagon responsiveness was absent at diagnosis, transiently improved at 6 months (p=0.04), absent at 12 months, and paradoxically suppressed at 18 months (p=0.02). Basal glucagon levels remained stable over time. Glucagon responses correlated positively with CGM time-in-range (70\u2013180\u2009mg\/dL) and negatively with glycemic variability and hypoglycemia frequency. A CGM-based logistic model integrating these metrics predicted impaired glucagon responses with good discrimination (area under the curve 0.79). Circulating glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, tumor necrosis factor-\u03b1, and interferon-\u03b3 correlated positively with glucagon secretion, whereas partial remission status did not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Glucagon counterregulation is profoundly impaired early in pediatric T1D and deteriorates dynamically within the first 18 months after diagnosis. Glycemic instability and recurrent hypoglycemia are key determinants of \u03b1-cell dysfunction. CGM-derived metrics may serve as non-invasive surrogates of impaired counterregulation and support early risk stratification for hypoglycemia in children with T1D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06770621\">NCT06770621<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjdrc-2026-005959","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:35:44Z","timestamp":1787740544000},"page":"e005959","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Early loss and progressive deterioration of glucagon responses to hypoglycemia in children with type 1 diabetes"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct06770621","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06770621","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Antoine","family":"Harvengt","sequence":"first","affiliation":[{"name":"P\u00f4le EDIN, UCLouvain, Woluw\u00e9 Saint Lambert, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maude","family":"Beckers","sequence":"additional","affiliation":[{"name":"P\u00f4le EDIN, UCLouvain, Woluw\u00e9 Saint Lambert, Belgium"},{"name":"Specialized Pediatrics Service, Cliniques universitaires Saint-Luc, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilektra","family":"Iakovidou","sequence":"additional","affiliation":[{"name":"P\u00f4le EDIN, UCLouvain, Woluw\u00e9 Saint Lambert, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Maure","sequence":"additional","affiliation":[{"name":"P\u00f4le EDIN, UCLouvain, Woluw\u00e9 Saint Lambert, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Syed","sequence":"additional","affiliation":[{"name":"P\u00f4le EDIN, UCLouvain, Woluw\u00e9 Saint Lambert, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Boutsen","sequence":"additional","affiliation":[{"name":"Specialized Pediatrics Service, Cliniques universitaires Saint-Luc, Brussels, Belgium"},{"name":"Pediatric Service, CHU UCL Namur, Yvoir, Walloon Region, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Beckers","sequence":"additional","affiliation":[{"name":"Pediatric Service, CHU UCL Namur, Yvoir, Walloon Region, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1598-7998","authenticated-orcid":false,"given":"Philippe A","family":"Lysy","sequence":"additional","affiliation":[{"name":"P\u00f4le EDIN, UCLouvain, Woluw\u00e9 Saint Lambert, Belgium"},{"name":"Specialized Pediatrics Service, Cliniques universitaires Saint-Luc, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2026082603350528000_14.4.e005959.1","doi-asserted-by":"crossref","unstructured":"Sandoval DA , D\u2019Alessio DA . Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015;95. doi:10.3389\/fendo.2026.1758848","DOI":"10.1152\/physrev.00013.2014"},{"key":"2026082603350528000_14.4.e005959.2","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15009","article-title":"Mini-review: Glucagon responses in type 1 diabetes - a matter of complexity","volume":"9","author":"Bisgaard Bengtsen","year":"2021","journal-title":"Physiol Rep"},{"key":"2026082603350528000_14.4.e005959.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.182.4108.171"},{"key":"2026082603350528000_14.4.e005959.4","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2612"},{"key":"2026082603350528000_14.4.e005959.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2010"},{"key":"2026082603350528000_14.4.e005959.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3486-3"},{"key":"2026082603350528000_14.4.e005959.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.02.032"},{"key":"2026082603350528000_14.4.e005959.8","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41574-018-0097-y","article-title":"The \u03b1-cell in diabetes mellitus","volume":"14","author":"Gromada","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2026082603350528000_14.4.e005959.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.12.001"},{"key":"2026082603350528000_14.4.e005959.10","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0164"},{"key":"2026082603350528000_14.4.e005959.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-04471-w","article-title":"Islet delta-cell architecture is remodelled in the human pancreas during type 1 diabetes","volume":"15","author":"Tegehall","year":"2025","journal-title":"Sci Rep"},{"key":"2026082603350528000_14.4.e005959.12","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0284"},{"key":"2026082603350528000_14.4.e005959.13","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0728"},{"key":"2026082603350528000_14.4.e005959.14","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13443"},{"key":"2026082603350528000_14.4.e005959.15","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S002"},{"key":"2026082603350528000_14.4.e005959.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.2047-6310.2012.00064.x"},{"key":"2026082603350528000_14.4.e005959.17","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1987"},{"key":"2026082603350528000_14.4.e005959.18","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/73.3.751"},{"key":"2026082603350528000_14.4.e005959.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.2041-210x.2012.00261.x"},{"key":"2026082603350528000_14.4.e005959.20","doi-asserted-by":"crossref","unstructured":"Bates D , M\u00e4chler M , Bolker B , et al . Fitting linear mixed-effects models using lme4. doi:10.18637\/jss.v067.i01","DOI":"10.18637\/jss.v067.i01"},{"key":"2026082603350528000_14.4.e005959.21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest Package: Tests in Linear Mixed Effects Models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J Stat Soft"},{"key":"2026082603350528000_14.4.e005959.22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00125-020-05361-8","article-title":"Hyperinsulinaemic-hypoglycaemic glucose clamps in human research: a systematic review of the literature","volume":"64","author":"Fabricius","year":"2021","journal-title":"Diabetologia"},{"key":"2026082603350528000_14.4.e005959.23","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1210\/jcem-72-6-1388","article-title":"SUPPRESSION OF COUNTERREGULATORY HORMONE RESPONSE TO HYPOGLYCEMIA BY INSULIN PER SE","volume":"72","author":"Diamond","year":"1991","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"2026082603350528000_14.4.e005959.24","first-page":"1293","article-title":"Effect of physiological hyperinsulinemia on counterregulatory hormone responses during hypoglycemia in humans","volume":"75","author":"Mellman","year":"1992","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"2026082603350528000_14.4.e005959.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05947-y"},{"key":"2026082603350528000_14.4.e005959.26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4158\/EP15984.RA","article-title":"THE ROLE OF GLUCAGON IN THE PATHOPHYSIOLOGY AND MANAGEMENT OF DIABETES","volume":"22","author":"Kulina","year":"2016","journal-title":"Endocr Pract"},{"key":"2026082603350528000_14.4.e005959.27","doi-asserted-by":"crossref","first-page":"E1074","DOI":"10.1152\/ajpendo.00379.2020","article-title":"Co-impairment of autonomic and glucagon responses to insulin-induced hypoglycemia in dogs with naturally occurring insulin-dependent diabetes mellitus","volume":"319","author":"Gilor","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026082603350528000_14.4.e005959.28","doi-asserted-by":"publisher","DOI":"10.2337\/db06-1454"},{"key":"2026082603350528000_14.4.e005959.29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s42255-019-0148-2","article-title":"Integrating the inputs that shape pancreatic islet hormone release","volume":"1","author":"Noguchi","year":"2019","journal-title":"Nat Metab"},{"key":"2026082603350528000_14.4.e005959.30","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.2147\/DMSO.S343514","article-title":"The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review","volume":"14","author":"Guo","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2026082603350528000_14.4.e005959.31","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-1499"},{"key":"2026082603350528000_14.4.e005959.32","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12020-018-1750-x","article-title":"Impaired glucagon secretion in patients with fulminant type 1 diabetes mellitus","volume":"63","author":"Komada","year":"2019","journal-title":"Endocrine"},{"key":"2026082603350528000_14.4.e005959.33","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.2337\/dcS13-2030","article-title":"Glycemic variability: both sides of the story","volume":"36 Suppl 2","author":"Ceriello","year":"2013","journal-title":"Diabetes Care"},{"key":"2026082603350528000_14.4.e005959.34","doi-asserted-by":"crossref","DOI":"10.3390\/nu15132957","article-title":"Deep Analysis of Clinical Parameters and Temporal Evolution of Glycemic Parameters Based on CGM Data for the Characterization of Severe Hypoglycemia in a Cohort of Children and Adolescents with Type 1 Diabetes","volume":"15","author":"Harvengt","year":"2023","journal-title":"Nutrients"},{"key":"2026082603350528000_14.4.e005959.35","doi-asserted-by":"crossref","DOI":"10.3390\/nu17162610","article-title":"Development of a Prediction Model for Severe Hypoglycemia in Children and Adolescents with Type 1 Diabetes: The Epi-GLUREDIA Study","volume":"17","author":"Harvengt","year":"2025","journal-title":"Nutrients"},{"key":"2026082603350528000_14.4.e005959.36","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2026.1758848","article-title":"Clinical parameters and emerging biomarkers of partial remission in pediatric type 1 diabetes: a systematic review","volume":"17","author":"Dikranian","year":"2026","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2026-005959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:35:48Z","timestamp":1787740548000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2026-005959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjdrc-2026-005959"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2026-005959","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}